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Antibodies are the fastest-growing segment of the biologics market. The success of
antibody-based drugs resides in their exquisite specificity, high potency, stability, solubility,
safety, and relatively inexpensive manufacturing process in comparison with other
biologics. We outline here the structural studies and fundamental principles that define
how antibodies interact with diverse targets. We also describe the antibody repertoires
and affinity maturation mechanisms of humans, mice, and chickens, plus the use of
novel single-domain antibodies in camelids and sharks. These species all utilize diverse
evolutionary solutions to generate specific and high affinity antibodies and illustrate the
plasticity of natural antibody repertoires. In addition, we discuss the multiple variations
of man-made antibody repertoires designed and validated in the last two decades, which
have served as tools to explore how the size, diversity, and composition of a repertoire
impact the antibody discovery process.
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INTRODUCTION
In recent decades, rodent monoclonal antibodies obtained by
hybridoma technology and engineered bymolecular biology tech-
niques, or human antibodies obtained by display technologies or
B-cell cloning, have become the treatment of choice in diverse
diseases such as multiple sclerosis, rheumatoid arthritis, and sev-
eral types of cancers, making a significant component of the
pharmaceuticals market (Nelson et al., 2010). The success of
therapeutic antibodies, with as many as 28 antibodies and anti-
body fragments marketed in The United States or The European
Union (Reichert, 2012), resides in their exquisite specificity, high
potency, stability, solubility, clinical tolerability, and relatively
inexpensive manufacturing process in comparison with other
biologics.
The factors contributing to the specificity and potency of
antibodies have intrigued scientists since their discovery in the
late 1800s and only in the last three decades has a clear pic-
ture of how antibodies work emerged. The current knowledge
base has been assembled by combining insights from multiple
disciplines such as: structural biology—studying hundreds of
x-ray crystallography antibody structures from different species
(Davies and Metzger, 1983; Chothia and Lesk, 1987; Wilson and
Stanfield, 1994; Stanfield and Wilson, 2010) free and in com-
plex with a wide variety of ligands (MacCallum et al., 1996;
Ragunathan et al., 2012); immunogenetics—by fully characteriz-
ing the germline gene antibody repertoire of humans and other
species (Lefranc et al., 2005) and by deciphering the molecu-
lar mechanisms used to generate functional antibody molecules
starting from diverse gene families (Tonegawa, 1983); and cellular
immunology—dissecting the process by which in vivo selec-
tion of specific antibodies occurs during an immune response
and understanding the mechanisms that allow the affinity and
specificity of the selected antibodies to mature as the immune
response progresses (Noia and Neuberger, 2007).
The accumulation of this knowledge has potentiated several
technological advances in the antibody engineering field, such as
humanization of non-human antibodies to increase their human
content and to enhance their manufacturability profile (Gilliland
et al., 2012), the development of display technologies to select
specific human antibodies in vitro (Hoogenboom, 2005), and
the engineering of antibody characteristics such as affinity, cross-
reactivity with target orthologs, stability, and solubility. Each of
these great leaps forward have relied directly on a core of funda-
mental immunological knowledge and made it possible to create
close to 30 antibody-based drugs, at the time of writing.
Here, we first provide an overview of the antibody structure
and outline the fundamental principles that define how antibod-
ies interact with diverse ligands. In the second section, we review
the current knowledge of the antibody repertoire of humans and
experimental species commonly used to generate monoclonal
antibodies such as mice, chickens, and camelids. Each of these
species possess distinct germline gene repertoires, have differing
mechanisms of generating and affinity maturing their antibody
molecules and, therefore, offer alternative sources of specific vari-
able regions for therapeutic antibody development. In the third
section, multiple variations ofman-made antibody repertoires are
described, from their inception to the current state of the art.
These designer repertoires have applied the compound knowl-
edge derived from both structural and repertoire studies, serving
as tools to test hypotheses on how the size of a repertoire, its
diversity and composition impact the selection of more specific
and higher affinity antibodies. These repertoires have also been
used extensively by academic laboratories and biotech companies
to discover and optimize human antibodies in vitro. At the end
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of the article, a section with conclusions and future directions is
included.
THE ANTIBODY MOLECULE
The IgG isotype is the most abundant form of circulating anti-
body and the molecular format of choice for most marketed ther-
apeutic antibodies (Reichert, 2012), as it is stable, soluble, readily
expressed in heterologous systems such as Chinese hamster ovary
(CHO) cells and can potentially engage effector functions such
as antibody-dependent cell-mediated cytotoxicity (ADCC) and
complement-dependent cytotoxicity (CDC). IgGs are Y-shaped
glycoproteins of approximately 150 kDa composed of two iden-
tical polypeptide heavy (H) chains and two identical light (L)
chains. The most abundant classes of L chains are κ and λ, which
are functionally indistinguishable, but structurally different and
vary in proportion in different species. For instance, the human
repertoire is approximately 40:60λ:κ, whereas, the mouse reper-
toire is ∼95% κ-type. The H chain divides Igs into five classes,
IgG, IgD, IgE, IgA, and IgM, each with a unique role in the
adaptive immune system.
By digesting IgGs with papain, two fractions can be obtained,
one containing the so-called crystallizable fragment (Fc) and the
other containing two identical antigen-binding fragments or Fabs
(Figure 1). In the Fc resides the effector functions, whereas, the
Fab, as its name indicates, binds the antigen and thus defines the
specificity of antibodies. Each Fab has two variable domains, one
from the H chain (VH) and another from the L chain (VL), in
addition to two C domains: CH1 and CL. The Fc is a dimer made
of four C domains, two CH2 and two CH3 domains.
The first antibody structures, solved in the 1970s [for early
reviews see (Padlan, 1977; Amzel and Poljak, 1979; Davies
and Metzger, 1983) and for more current reviews see (Wilson
and Stanfield, 1994; Stanfield and Wilson, 2010)], revealed that
FIGURE 1 | Ribbon representation of an intact IgG molecule
(PDBID: 1IGT). The heavy chains are shown in dark blue, while the Light
chains are colored in light blue. The carbohydrate moieties attached to the
CH2 domains are represented with sticks. The figure was produced using
PyMol (DeLano, 2002. The PyMOL molecular graphics system. Delano
Scientific, San Carlos, CA).
V- and C-domains have a conserved and similar structure, termed
“immunoglobulin (Ig) fold.” The Ig fold is also the building block
of a large number of other proteins with diverse functions, which
are collectively called the Ig superfamily (Williams and Barclay,
1988). The Ig fold consists of two anti-parallel β-sheets that are
tightly packed together. In the C domain, one of the β-sheets is
formed by four β-strands A to D, whereas, the other β-sheet is
formed by three β-strands C to G (Figure 2). A conserved intra-
domain disulfide bridge, formed between cysteine residues in
the B and F β-strands, stabilizes the C domain. The V-domain
have an insertion with respect to the C domain of two extra
β-strands, identified as C’ and C”, present between β-strands C
and D (Figure 2). As in the C domain, an intra-domain disulfide
bridge is formed between cysteine residues in β-strands B and F.
The V-domains are in general less compact than the C domains
with some longer loops connecting the β-strands. This flexibil-
ity and the longer loops contribute to the mechanism of antigen
binding, thus defining the capability of antibodies to recognize
diverse antigens.
THE ANTIGEN-BINDING SITE
The antigen binding site is principally defined by the
Complementarity-Determining Regions (CDRs). These regions
were originally identified by amino acid sequence variability
analysis (Wu and Kabat, 1970; Kabat and Wu, 1971) as highly
variable regions within the V-domains. The CDRs were defined
prior to our knowledge of the mechanisms by which antibodies
are generated and predated the three-dimensional structure
solution of antibodies. Once the first Fab structures were solved,
it was realized that the CDRs approximately correspond to loops
that vary in structure, called hypervariable loops (HVLs). Each
V-domain contributes three CDRs to the antigen-binding site:
CDR-L1, CDR-L2, and CDR-L3 from the VL and CDR-H1,
FIGURE 2 | Ribbon representation of a VH (left) domain and a CH1
(right) domain. CDRs are colored in yellow (CDR-1), orange (CDR-2), and
red (CDR-3). Note the insertion in the VH domain with respect to the CH1
domain of two β-strands, C’ and C”, and the loop linking them, which
contains the CDR-H2. The coordinates used to produce the Figure were the
same as in Figure 1. The figure was generated with PyMol.
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CDR-H2, and CDR-H3 from the VH. The three CDRs from VH
and the three from VL are brought together by non-covalent
association of the V-domains at the N-terminal region of the Fv
(Figure 3). The remaining portion of the V-domain, i.e., the two
β-sheets and non-HVLs, generally provide structural support to
the antigen-binding site, rather than making contact with antigen
and are thus referred to as framework regions (FRs). However,
the sequence variability observed in the FRs is not irrelevant to
functional binding diversity, as it can directly affect CDR loop
conformation and the orientation of VH–VL pairing (Foote and
Winter, 1992; Abhinandan and Martin, 2010).
Given the essential variability of the antigen-binding site,
which must be capable of recognizing a large array of diverse
antigens to fulfill its remit, it was initially thought that each anti-
body possesses a unique conformation at the antigen-binding site.
Nevertheless, analysis (Chothia and Lesk, 1987; Chothia et al.,
1989) in the late 1980s of a small set of structures of immunoglob-
ulin fragments available at the time revealed that, although the
HVLs vary in sequence, five out of the six HVLs (CDR-L1,
CDR-L2, CDR-L3, CDR-H1, and CDR-H2) had a limited set of
main-chain conformations or “canonical structures.” The canoni-
cal structure model implied a paradigm shift in the field, replacing
the notion that each antibody has unique HVL conformations
and thus overall unique antigen-binding site structure. The lim-
ited set of canonical structures helped to develop 3D modeling
structure strategies (Martin and Thornton, 1996) and suggested
that structural constraints are at work in antigen recognition.
A canonical structure is defined by the HVL length and con-
served residues located in the HVL and FR (Chothia and Lesk,
1987). Overall, the structural repertoire generated by λ-type
chains is broader than that of κ-type chains (Chailyan et al.,
2011). In the latter, all the canonical structures at CDR-L1
follow a similar pattern, which consists of an extended con-
formation between residues 26 and 29 [Chothia’s numbering;
FIGURE 3 | Ribbon representation of a Fv fragment seen from the
antigen perspective. VH is colored in dark blue, while VL is colored in light
blue. CDRs are colored in yellow (CDR-1), orange (CDR-2), and red (CDR-3).
The coordinates used to produce the Figure are the same as in Figure 1.
The Figure was generated with PyMol.
(Al-Lazikani et al., 1997)], and hairpin loops of different lengths
encompassing residues 30–32, with up to seven insertions in
this segment of the loop. The CDR-L2 adopts a single con-
formation. Most (∼70%) of the CDR-L3 loops have a single
canonical structure. In contrast, the CDR-L1 of λ-type chains
adopts a helical structure with up to eight conformations and
an average root mean square deviation (RMSD) between loops
of 2.3 Å (Chailyan et al., 2011). The λ-type CDR-L2 usually
adopts a similar hairpin loop conformation to that of κ-type,
but can in some instances have an insertion of four residues,
which leads to another canonical structure. The CDR-L3 in
λ-type antibodies has a broader variety of lengths and confor-
mations than κ-type antibodies, with only a small fraction of the
loops following a defined canonical structure (Chailyan et al.,
2011).
The CDR-H1, similar to the CDR-L1, has an extended con-
formation linking β-strands from the two β-sheets that form the
Ig fold. However, it is less diverse than its counterpart in VL, with
three canonical structures and a strong bias (∼85%) (Ragunathan
et al., 2012) toward the shortest loop (seven residues). The reper-
toire of canonical structures of CDR-H2 is less skewed than
that for CDR-L3 and CDR-H1, with six canonical structures.
Still, 59–70% of the antibodies (Ragunathan et al., 2012) have a
six-residue canonical structure.
Recently, the application of clustering algorithms (North et al.,
2011) on 300 non-redundant antibody structures has further
stratified the canonical structure combinations by identifying 28
HVL combinations of lengths for the loops with canonical struc-
tures, whereas, previous analysis (Al-Lazikani et al., 1997) covered
only 20. Only four of these clusters had more than one con-
formation, of which two could be distinguished by gene source
(mouse/human; κ/λ) and one could be distinguished solely by
the presence and position of Proresidues in the CDR-L3. Of the 28
CDR-lengths, 15 havemultiple conformational clusters, including
10 for which previous analysis had only one canonical structure
combination.
The CDR-H3, localized at the center of the antigen-binding
site, is by far the most variable loop in length and sequence of
the CDRs (Chothia and Lesk, 1987; Wu et al., 1993; Zemlin et al.,
2003). The diversity of the CDR-H3 comes from the recombina-
tion of three germline genes: IGHV, IGHD, and IGHJ (Tonegawa,
1983), imprecise recombination of these genes, i.e., junctional
diversity (Alt and Baltimore, 1982), the possibility of using three
reading frames for translation of the IGHD gene (Sanz, 1991),
and further diversification during somatic hypermutation process
(see below).
Human CDR-H3 loops have an average length of 15.2 (±4.1)
residues (IMGT CDR definition) (Zemlin et al., 2003), with a
range of lengths between 1–35 residues, and a length distribu-
tion resembling a Gaussian process. While extensive analysis of
antibody structures has identified sequence patterns to predict
the conformation of the residues at the base of the CDR-H3
(Shirai et al., 1996; Morea et al., 1998), the enormous variabil-
ity in amino acid sequence and length of this loop, as well as
its flexibility, has precluded delineation of rules for predicting its
overall conformation. Thus, structural modeling of CDR-H3 is
still challenging (Almagro et al., 2011), using either comparative
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methods that rely on templates chosen based on sequence homol-
ogy, or knowledge-based methods such as the canonical structure
model.
STRUCTURE-FUNCTION RELATIONSHIPS AT THE
ANTIGEN-BINDING SITE
Since antibodies have a small subset of canonical structures in
five of the six loops that define the antigen-binding site, it is
reasonable to hypothesize that only a limited subset of antigen-
binding site geometries exists, and the arising questions are
whether the general architecture of the antigen-binding site can
be predicted and whether it correlates with antigen recognition
(Vargas-Madrazo et al., 1995). Finding structure-function corre-
lations at the antigen-biding site holds the promise of providing
insights into the mechanism of the molecular recognition process
used by antibodies to bind diverse antigens and thereby to assist
the rational design of antibodies of desired specificity.
Initial work (Vargas-Madrazo et al., 1995) showed that from a
total of 300 possible canonical structure combinations described
at that time, only 10 exist in 90% of the sequences analyzed.
The existing canonical structure combinations were classified in
two sets: one with preference for some specific types of antigens
like proteins, peptides or haptens, and other with multi-specific
binding capabilities. In the specific classes, the length of CDR-
H2 and CDR-L1 was found to correlate with the type of antigen,
whereas, in the multi-specific classes, such a correlation could not
be established. A recent study (Ragunathan et al., 2012) of 140
unique antigen-antibody complexes has corroborated that most
of the anti-protein antibodies have canonical structures deter-
mined by short CDR-L1 loops (6–8 residues). This is in contrast
to anti-peptide and anti-hapten antibodies, which predominantly
have canonical structures made of long CDR-L1 loops (11–
13 residues). The remaining loops show little difference in the
canonical structure distribution across anti-protein, anti-peptide,
and anti-hapten antibodies.
Figure 4 overlays 99 unique mid to high resolution (≤3.0 Å)
antibody structures, including 30 in complex with proteins, 34
with peptides, and 35 with haptens. As can be seen, the topog-
raphy of the antigen-binding site tends to determine the size
of the antigen with which the antibody interacts. Anti-protein
FIGURE 4 | Trace representation of 99 unique mid to high resolution
(= 3.0 Å) Fv structures, including 30 in complex with proteins, 34 with
peptides, and 35 with haptens. VH colored in dark blue. VL colored in light
blue. Ligands are colored in orange. The coordinates used to generate the
Figure are listed in Ragunathan et al. (2012). The structures were
superposed in Discovery Studio using the FR Cα atoms.
antibodies tend to have flatter binding sites than anti-peptide
antibodies. The antigen-binding of anti-peptide antibodies is
grooved, mainly determined by the long CDR-L1, which accom-
modates the peptides at the center of the antigen-binding site.
Anti-hapten antibodies have a smaller antigen-biding site with
contacts with haptens being buried deeper in the VH:VL interface
where proteins and peptides cannot reach.
In non-specific classes, the CDR-H3 plays a predominant role
in defining the topography of the binding site (Vargas-Madrazo
et al., 1995). Short CDR-H3 loops can create a cavity in the
antigen-binding site to accommodate peptides. Long CDR-H3
loops are found in antibodies associated with chronic viral infec-
tions, in contrast to antibodies from acute viral infections, which
have relatively short CDR-H3 loops (Breden et al., 2011). Long
and extended CDR-H3 loops can generate a definite type of struc-
ture, called finger-like topography (Saphire et al., 2001), which
differ from the typical flat anti-protein binding-site. This finger-
like topography allows antibodies to access recessed epitopes in
the viral proteins.
The number of residues in contact with antigens also dif-
fers in antibodies recognizing proteins, peptides and haptens
(MacCallum et al., 1996; Almagro, 2004; Ragunathan et al., 2012).
The average number of contact residues in VL for the anti-protein,
anti-peptide, and anti-hapten antibodies is 9, 9, and 7, respec-
tively (Ragunathan et al., 2012). The corresponding values for
VH are 14, 12, and 10. A more detailed analysis of the sol-
vent accessible surface (SAS) that is buried upon antigen binding
and the location and frequency of contacts (called specificity-
determining residues usage, SDRUs) of antibodies in complex
with proteins, peptides or haptens also show distinctive patterns
(Almagro, 2004). Anti-protein antibodies have an average (±SD)
SAS value of 737 (±272) Å2 with hotspots of SDRUs located at
the edge of the antigen-binding site (Ragunathan et al., 2012).
Anti-hapten antibodies have a roughly 2-fold smaller SAS value
of 374 (±117) Å2 with hotspots of SDRUs placed in the interior
of the antigen-binding site or even buried in the VL:VH interface.
Anti-peptide antibodies have a SAS value of 544 (±158) Å2, which
is in between anti-protein and anti-hapten antibodies. The SDRU
hotspots of anti-peptide antibodies are located in the interior of
the antigen-binding site but not buried in the VL:VH interface as
with anti-hapten antibodies.
Combining the SDRU patterns with the distinctive shape of
the antigen-binding site of antibodies recognizing different types
of antigens lead to the conclusion that anti-protein antibodies
tend to have flatter and larger binding sites than anti-peptide
and anti-hapten antibodies. The antigen-binding of anti-peptides
is grooved, whereas, anti-hapten antibodies have a smaller and
deeper antigen-biding site, with SDRU hotspots buried in the
VH:VL interface (Figure 5).
Since SDRUs are a measure of the likelihood of establish-
ing contacts with the antigen, they can provide a definition
of the antigen-binding site in absence of the antigen-antibody
complex structure. A definition of the antigen-binding site
based on SDRUs could thus guide the selection of residues
to transfer the specificity from a given antibody into a dif-
ferent scaffold, either to produce a molecule with enhanced
biophysical profile such as increased stability (Ewert et al.,
Frontiers in Immunology | B Cell Biology November 2012 | Volume 3 | Article 342 | 4
Finlay and Almagro Antibody repertoires
FIGURE 5 | Connolly (1983) surfaces of representative anti-protein,
anti-peptide and anti-hapten Fvs, shown from the antigen perspective.
A gradient from red (contact) to white (no contact) represents the SDRUs
of antibodies recognizing generic ligands. The surfaces were generated by
running a 7.0-Å radius probe over the Fv after removing the CDR-H3 loop
(yellow ribbon) to better represent the surface common to all antibodies.
Note the variation in size of the surface from anti-protein, a large surface, to
anti-hapten antibodies, a small one. On the bottom, a ribbon representation
of a Fv in the same orientation as the Fvs displaying the Connolly surface to
indicate the position of the CDRs. Also note the protruding CDR-L1 in the
anti-peptide and anti-hapten Fvs, which modulates the topography of the
antigen-binding site. The ribbon figure was generated with PyMol, while
the Connolly surface figures were produced using Discovery Studio.
2004) and/or to humanize a nonhuman antibody (Almagro
and Fransson, 2008). Importantly, protocols using SDRUs can
tailor humanization of antibodies recognizing different types
of ligands, thereby minimizing the region of the non-human
antibody grafted into the human context and hence potential
immunogenicity.
Not all amino acids are equally used to contact antigens
and the types of antibody residues involved in contacts with
proteins, peptides, and haptens also differ. Tyrosine (Y), argi-
nine (R), asparagine (N), aspartic acid (D), histidine (H), ser-
ine (S), and threonine (T) make more contacts than other
amino acids in all the three antigen types. Of particular inter-
est is Y, which has been found in a high proportion in the
antigen-binding site of antibodies. For instance, Lo Conte et al.
(1999) observed that Y contributed to 16.6% of all amino acids
in contact in the 19 antigen-antibody complexes available at
that time. Similarly, an earlier report by Mian et al. (1991)
based on the analysis of only six antibody–antigen complexes
reported the overuse of Y to contact antigens. Cysteine (C),
proline (P), glutamine (Q), glutamic acid (E) and hydropho-
bic amino acids such as alanine (A), valine (V), isoleucine (I),
leucine (L), methionine (M) and phenylalanine (F) make signif-
icantly fewer contacts. Thus, hydrophilic amino acids predomi-
nate over hydrophobic ones. In the CDR-L1, N, and D are the
most frequent residues in contacts. R is rare and tryptophan
(W) does not occur. CDR-L2 has less diversity than CDR-L1
and CDR-L3, and in the latter, most contacts involve amino
acids S, T, W, and Y, whereas, R, N, G, and H make fewer
contacts.
A detailed analysis of the contribution of each amino acid
called Specificity-Determining Residues Matrix (SDRM) to each
SDRU depending upon the type of antigen the antibody inter-
acts with have been described by Ragunathan et al. (2012).
Briefly, there are more D and T contacts in anti-protein anti-
bodies in CDR-L1 than anti-peptide and anti-hapten antibodies.
In CDR-L3, anti-protein antibodies have more R and W con-
tacts, whereas, anti-hapten antibodies have more Q, G, and H
contacts. Similar to VL, S, T, and Y dominate the contacts for
VH. Likewise, C, P, Q, D and hydrophobic amino acids are sig-
nificantly underrepresented at contact residues. Interestingly, VH
has more contacts involving negatively charged amino acids and
fewer K residues in comparison to VL. In CDR-H1, N, G, S, T,
and Y predominant in contact sites for all antibodies. In addition,
D occurs frequently in anti-protein and anti-peptide antibod-
ies. The detailed picture of the contribution of each amino acid
(SDRM) to each SDRU depending upon the type of antigen
the antibody interacts with has practical applications to design
antibody repertoires.
THE ANTIBODY REPERTOIRE IN HUMANS AND
IMMUNIZATION OF HOST SPECIES
In addition to the structural studies outlined above, antibody
repertoire analyses and comparative immunogenetics have been
highly informative approaches to understanding how antibod-
ies evolved to recognize diverse antigen structures. Indeed, the
lessons learned from such studies have been critical factors in
the progress of antibody engineering. For example, a profound
understanding of the biases inherent in the functional repertoire
of human antibodies, in comparison to those of other species
(Schroeder et al., 1995; Zemlin et al., 2003; Schroeder, 2006)
inspired experimental work to define the critical biochemical
characteristics required to form a functional synthetic antibody
repertoire (Fellouse et al., 2006; Birtalan et al., 2008, 2010). To
further illustrate the important influence these studies, below
we outline what has been learned about the human antibody
repertoire and several other species of interest in antibody discov-
ery and highlight how this knowledge is impacting the antibody
engineering field.
THE HUMAN ANTIBODY REPERTOIRE
The primary repertoire of antibodies is produced via the com-
binatorial rearrangement of IG (H, K, or L)V with IGHD (only
in VH) and IG (H, K, or L)J germline genes, followed by pair-
ing of VH and VL domains (Tonegawa, 1983). This repertoire
should be diverse and versatile enough to recognize any anti-
gen with a low or medium affinity during the primary immune
response (Neuberger and Milstein, 1995). The physical maps of
the human IGH and IGL gene loci were elucidated in the 1990s
(Tomlinson et al., 1992; Schäble et al., 1994; Matsuda et al.,
1998) and the information has been compiled and annotated at
The ImmunoGenetics Database (IMGT; http://www.imgt.org/).
This information has provided the foundations to understand the
mechanisms of generation of diversity in human antibodies and
has shed light on the evolution of the antibody repertoire.
Overall, the human IGK locus contains approximately 30 func-
tional IGKV genes distributed in six families, and five IGKJ
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segments which recombine to form the primary Vκ repertoire.
There are 30–36 functional IGLV genes arranged in three distinct
clusters containing 11 IGLV gene families and four functional Cλ
domains, each with its own IGLJ gene. The IGH locus contains
approximately 39 functional IGHV genes distributed in seven
IGHV gene families, approximately 30 IGHD segments classi-
fied also in seven families and six IGHJ genes. As more human
germline genes from diverse individuals have been sequenced and
studied, an increasing number of alleles have been compiled at
IMGT (Lefranc et al., 2005).
Analysis of the antibody genes amplified from diverse sources
(Cox et al., 1994; Huang et al., 1996; Ignatovich et al., 1997;
Brezinschek et al., 1998; de Wildt et al., 1999; Farner et al., 1999;
Glanville et al., 2009) indicates a strong bias in gene usage. For
instance, only five IGHV genes (5–51, 1–69, 1–2, 4–59/61, and
3–30/33) make 50% of the rearranged antibodies and only 24 out
of 39 functional genes (∼60%) are expressed with a frequency
above 1% (Glanville et al., 2009). For IGVK the bias is more
dramatic. Only three IGVK genes (3–20, 1–39, and 3–15) make
50% of the rearranged antibody repertoire and only 16 out of 30
genes are expressed with a frequency of more than 1%. Pairing
of heavy and light chains in B cells (de Wildt et al., 1999) and
in recombinant libraries (Glanville et al., 2009) appears to be a
random process, reflecting the relative abundance of the IGHV
and IGLV gene family members. The bias in the gene usage
is due to a number of factors including position in the locus,
ontogenetic regulation of the immune response, gene copy and
binding properties of the antibodies encoded by certain genes
(Dal-Bo et al., 2011; Lerner, 2011; Zhu et al., 2011).
After antibody exposure to antigen, an affinity maturation
process generates diversity from which antibodies with higher
affinity are selected, as the antigen concentration decreases dur-
ing the secondary immune response. Affinity maturation mech-
anisms include somatic hypermutation (in most mammalian
systems) and gene conversion (in certain species, see below).
The somatic hypermutation process takes place in the germi-
nal centers with the help of T-cells. The V-genes in activated
B cells undergo activation-induced (cytidine) deaminase (AID)-
catalyzed somatic hypermutation at a rate of up to 10−3 changes
per base pair per cell cycle (Rajewsky et al., 1987). Two separate
mechanisms are involved in the mutation process (Maizels, 2005);
one targets mutation hotspots with the RGYW (R = purine, Y =
pyrimidine, W = A or T) motif (Dörner et al., 1998) which
includes the reverse complement of the preferential substrate site
for AID, while the second incorporates an error-prone DNA syn-
thesis that can lead to a nucleotide mismatch between the original
template and the mutated DNA strand (Rada et al., 1998). The
overall process favors single-base transitions over transversions at
a 3:1 ratio (Betz et al., 1993).
The frequency of mutations in VH and VL are qualitatively
similar, following an exponential distribution with as much as
15–20% of the V-regions showing no mutations at the amino
acid level (Tomlinson et al., 1996; Ramirez-Benitez and Almagro,
2001). The average number of mutations per V-region has been
estimated for humans and mice to be around 8 and 5 mutations
for VH and VL, respectively (Tomlinson et al., 1996; Ramirez-
Benitez and Almagro, 2001; Clark et al., 2006). Although the
mutations are spread throughout the V-domains, they occur at a
proportion of 3:2:1 mutations at the antigen-binding site, surface
of the V-domains and VL:VH interface, and core of the V-domain,
respectively (Clark et al., 2006). The relatively high proportion of
mutations in the CDRs with respect to FRs is explained in part
by a higher concentration of mutation hotspots in the former.
It also reflects the selection for affinity improvement, although
it has been found that somatic mutations in residues in direct
contact with antigen are less frequent than in residues adjacent
to the residues in contact (Ramirez-Benitez and Almagro, 2001),
suggesting that the residues selected during the primary immune
response do not change during the affinity maturation. Insertions
and deletions also occur but at a lower rate (Wilson et al., 1998;
Zhao and Lu, 2010), implying that the overall geometry of the
antigen-binding site as defined by the canonical structures does
not change significantly during the affinity maturation process
either.
The amino acid content and length distribution of the
CDR-H3 region is of critical importance to antibody repertoire
function and the diversity encoded in this loop in humans has
been extensively characterized to aid synthetic mimicry of human
diversity (Schroeder et al., 1987; Zemlin et al., 2003; Schroeder,
2006; Glanville et al., 2009). These studies have shown very clearly
that the human CDR-H3 repertoire is distinctly different from
that of the mouse, particularly in length distribution. The human
loops tend to be significantly longer, at 15.2 (±4.1) residues,
while mice average at only 11.5 (±2.7) (Zemlin et al., 2003). Both
species exhibit common conserved motifs at the stem of the loop,
but the biases in amino acids used overall and, indeed, in a posi-
tional sense, show distinct differences. While humans and mice
both show a strong preference for the use of Y, S, and G residues,
this phenomenon is much more pronounced in mice (26% Y),
than humans (14% Y) and in both species this trend toward high
Y use increases proportionally with loop length. In humans in
particular, longer CDR-H3 loops are associated with increased use
of the IGHJ-6 segment, which encodes a series of contiguous Y
residues, increasing the frequency of Y content overall (Prassler
et al., 2011; Zhai et al., 2011). In addition, humans use more P
and do not exhibit the clear hallmarks of hydrogen bond ladder
formation in the loop as often as mice, suggesting more com-
plex overall loop topology in humans. This phenomenon may
be directly correlated with increased length in human CDR-H3,
with an associated higher use of cysteine via germline-encoded
“D2” DH sequences. These long D-segments encode for cysteine
residues spaced four amino acids apart, allowing disulphide loop
formation that can be critical to CDR secondary structure and
rigidity (Almagro et al., 2012). While these disulphide-stabilized
loops are relatively rare in humans (C = 1.21% of all amino
acid use in human CDR-H3), (Zemlin et al., 2003) they are a
commonly used motif in the antibodies of both chickens and
camelids, as outlined later.
HARNESSING NON-HUMAN ANTIBODY V-GENE REPERTOIRES
Species such as mouse, chicken and camelids (such as llama) are
all used as immune sources of antibodies with therapeutic poten-
tial. While antibodies from human libraries theoretically contain
“fully human” amino acid sequence in their FRs, antibodies from
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immune animal repertoires do not. Nonhuman-derived antibod-
ies may initially have their immunogenicity reduced by cloning
the V-genes onto a set of human C regions, to form a “chimeric”
antibody (Morrison et al., 1984). Even the small amount of
“foreign” amino acid content with respect to humans in the V-
domain FRs of a chimeric IgG may be enough to provoke an
anti-idiotypic antibody response, however, especially patients that
receive repeated doses of antibody as therapy (Stephens et al.,
1995). As a result, before clinical use, antibodies derived from
animals usually undergo a process of “humanization,” whereby
recombinant DNA technology is used to “graft” the CDRs of the
clone of interest onto human V-gene framework scaffolds (Jones
et al., 1986). It is typically necessary to carry out subsequent
V-gene engineering, e.g., via “back mutations” in the FRs, to
return the target binding affinity of the parental clone (Almagro
and Fransson, 2008). For this humanization process to be effi-
cient, it is helpful not only to be able to predict which human
FRs might be optimal to accept the grafted CDRs from a lead
clone, but also to understand the nuances of the structural char-
acteristics of the repertoire from which the clone was derived.
Armed with sufficient prior knowledge of each species’ reper-
toires, we can confidently predict the likely engineering path that
will be required to derive a fully active, but maximally humanized
product.
THE MOUSE ANTIBODY REPERTOIRE
The mouse (Mus muscullus) is the most widely usedmodel organ-
ism in immunology and perhaps in biology and medicine. For
the study of antibodies, the development of hybridoma technol-
ogy, first described by Köhler and Milstein (1975) and awarded
the Nobel Prize in 1984, was the key advancement that ultimately
led to development of antibody-based drugs. Hybridoma tech-
nology involves the immunization of rodents with an antigen
of interest and once a satisfactory immune response against the
antigen has been obtained, the antibody-producing B cells are
harvested and fused to a murine myeloma cell line. The result-
ing hybrid cells can be sub-cloned to generate clonal cell lines
in which every cell secretes antibodies with a single specificity.
Thus, hybridoma technology became an efficient means to pro-
duce unlimited amounts of single-specificity antibodies which
enabled the biochemical and structural characterization of anti-
bodies and the production of sufficient quantities of high quality
protein for therapeutic settings.
The physical maps of the mouse IGH and IGL gene loci were
elucidated in the second half of the 1990s (Tomlinson et al., 1992;
Schäble et al., 1994, 1999;Matsuda et al., 1998; Thiebe et al., 1999)
and, as for humans, the information is compiled and annotated
at IMGT (http://www.imgt.org/). The total number of mouse
(M. musculus) IGK genes per haploid genome is 164 (174 if the
orphons are included), of which 99 are functional, belonging
to 18 subgroups (Martinez-Jean et al., 2001). Eighty-one are in
opposite orientation of transcription, 59 of them are functional
and must rearrange by a mechanism of inversion. These genes
are recombined with five IGKJ genes. The IGL locus contains
only three IGLV genes each with one associated IGLJ gene. The
reduced contribution of the IGL locus to the mouse germline
repertoire is consistent with the approximately 8-fold reduction
in the prevalence of lambda-bearing IgG in the serum of mice
compared to humans.
The IGH locus is both larger and more diverse than that of
the humans (Schroeder, 2006). IMGT reported as of August 2012
two tables for the mouse IGVH germline gene repertoire. One
with IGHV genes compiled from diverse sources, which represent
genes characterized in several strains and thus some genes may be
alleles. The other table compiles data from the C57BL/6 Mouse
Genome Sequencing and is provisional since not all the genes
have been mapped and confirmed. It lists 170 IGVH germline
genes distributed in 15 IGHV gene families. One hundred one out
of the one hundred seventy known genes (∼60%) are functional
genes. These IGHV genes recombine with 21 functional IGDH
genes assorted in four families and four IGHJ functional genes.
Interestingly enough, comparisons of the canonical struc-
ture repertoire encoded in mouse and humans IGHV genes
(Almagro et al., 1997; Bono et al., 2004) indicate that the
human structural repertoire has two additional classes (1–1 and
1–3). Thus, the human repertoire is more diverse in structural
terms than that of mouse. In addition, the canonical struc-
ture class 1–2 is more prevalent in mouse (∼60%), while in
humans the dominant class is 1–3 (∼40%) (Almagro et al.,
1997). This divergence, together with phylogenetic analysis of
the human and mouse IGHV genes (Bono et al., 2004), indi-
cates that most of the sequences in the human and mouse
IGHV loci have arisen subsequent to the divergence of the two
organisms from their common ancestor. Identifying these dif-
ferences between human and mouse genes, which are perhaps
a reflection of functional and/or structural constraints at work
to balance the free diversification of the antibody repertoire in
humans and mice (Almagro et al., 1997), could be useful to
select the most human-like genes for humanization of mouse
antibodies.
THE CHICKEN REPERTOIRE
Gallus gallus, the domestic chicken, is a classic model for
immunological study. Indeed, “B-cell” derives from the term
“Bursal cell,” as B-cells were first recognized as products of the
Bursa of Fabricius, a cloaca-associated organ that is critical to
immune development in birds (Ratcliffe, 2006). The antibody
repertoire of chickens has also been extensively characterized in
functional isotype content and at the genomic level (Reynaud
et al., 1985, 1989; Ratcliffe, 2006). Their immunoglobulin system
is distinct from that of humans and mice as they have structural
equivalents of mammalian IgM, IgA, and IgG, but not IgE or IgD.
IgM is the major isotype expressed on the surface of their B-cells
(Ratcliffe, 2006). Additionally, all chicken antibodies useλ isotype
light chains, exclusively (Reynaud et al., 1987). Chicken IgG has
4 Cγ domains, however, and is thought to be a structural relative
of both mammalian IgG and IgE subclasses (Parvari et al., 1988).
Chicken IgG is also found in a “short” form, lacking the CH3 and
CH4 regions. Avian IgG is often described as “IgY” as it can be
found at high concentration in egg yolk, but it has been proposed
that the full-length form should be called IgG and the short form
IgY, to aid their differentiation (Ratcliffe, 2006).
The avian V-gene germline repertoire is extremely simple,
with single functional V-genes in both the light and heavy chains,
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that contain unique VL-JL and VH-D-JH segments (Reynaud
et al., 1989, 1991; Parvari et al., 1990). The chicken VL and
VH germline domains are highly homologous to stable and
soluble human Vλ and VH3 families (Ewert et al., 2002, 2003),
respectively, and this is maintained across the fully mature
repertoire (Wu et al., 2011). The uniformity of chicken V-gene
FW sequences renders them highly predictable in humanization
(Tsurushita et al., 2004; Nishibori et al., 2006). Despite this simple
V-gene system (Reynaud et al., 1983; Parvari et al., 1987a,b, 1988;
Ratcliffe, 2006), chickens have a broadly adaptable repertoire
that generates high affinity antibodies to protein, peptide and
hapten antigens (Yamanaka et al., 1996; Finlay et al., 2005, 2006;
Nishibori et al., 2006).
The chicken V-gene system is in stark contrast to that found
in humans, mice and primates, which all utilize a large set of
V-gene sequences that are highly diverse in both sequence and
structure (Schroeder et al., 1990; Schroeder, 2006). In chickens, as
in rabbits (Weill and Reynaud, 1992), a distinctly different set of
diversification mechanisms are used, including gene conversion
(Reynaud et al., 1987, 1989). Gene conversion relies on a single
template V-gene being diversified via the incorporation of seg-
ments from upstream pseudogenes that lack recombination signal
sequences. This process is used to diversify both the heavy and
light chains, with mutations being introduced into both CDRs
and FRs. For the process to be efficient, it relies on high sequence
homology between the pseudogene and the germline gene which
acts as the acceptor (Ratcliffe, 2006). A recent chicken VH reper-
toire analysis suggests the requirement for sequence homology
between germline and pseudogene leads to a low level of muta-
genesis in the FWs, but hypervariability in the CDRs (Wu et al.,
2011). Interestingly, this was coupled with strong maintenance of
common CDR structural residues that have also been observed
in mammals (Rader et al., 2000; Zemlin et al., 2003; Lee et al.,
2004), but modulation of residues that affect VH–VL interac-
tion (Padlan, 1994) and CDR structure (Foote andWinter, 1992).
The chicken VH repertoire therefore adds significant variability at
select FW positions to increase structural diversity, e.g., by chang-
ing the angle of interaction between the VH and VL domains
(Abhinandan and Martin, 2010).
The CDR-H3 repertoire of chickens differs distinctly from
that of humans and mice, in both length distribution and
amino acid content. Surprisingly, chickens have only 15 func-
tional D-segments, all of which are highly homologous and some
(e.g., D9/12/13, plus D4/8/11) are even identical in amino acid
sequence (Reynaud et al., 1991). Additionally, reading frame
1 predominates in chickens (Raaphorst et al., 1997), as read-
ing frames 2 and 3 create sequences containing stretches of
hydrophobic residues and stop codons, respectively (Reynaud
et al., 1991; Weill and Reynaud, 1992). This form of reading
frame control appears to be universal and has also been observed
(albeit in different reading frames) for; rabbits, sharks, mice,
primates, and humans (Raaphorst et al., 1997; Schroeder et al.,
1998; Schroeder, 2006). In reading frame 1, chicken D-segments
are biased toward the use of G, S, and Y, as observed in all
other vertebrate species studied to date (Zemlin et al., 2003;
Schroeder, 2006). In contrast to humans and mice however,
chicken D-segments obligately contain C, with the consensus
sequence G-S- (A/G)-Y-C- (G/C)- (S/W)-X-A- (Y/E) (X = non-
conserved) (Reynaud et al., 1991). This limited initial VH CDR3
repertoire is hyper-diversified both by somatic mutation and the
insertion of new sequences via gene conversion. These D-like
sequences are donated by pseudogenes and may replace the entire
D-segment or only a small section, leading to the creation of
“mosaic CDRs” (Reynaud et al., 1989, 1991).
Analyses of CDR-H3 amino acid content in the chicken shows
very different paratope chemical composition in comparison to
humans andmice (Wu et al., 2011). There is a distinct bias toward
small amino acids G/S/A/C/T (but not P), while large aromatic
and hydrophobic residues are strongly disfavored, including an
unusually low representation of Y, the dominant residue in the
repertoires of mice and humans (Zemlin et al., 2003). This obser-
vation may be important, as synthetic antibody repertoire studies
have suggested that Y is a critical amino acid for target binding
(Fellouse et al., 2004, 2005, 2006, 2007). Additionally, the chicken
CDR3 repertoire has low representation of positively charged
residues (K/R). This may be of practical importance, as excess
positive charge in the VH CDR3 is associated with polyreactivity
(Li et al., 2001) and poor pK profile in vivo (Boswell et al., 2010).
The use of C in the CDR-H3 of >50% of all B-cell clones
in the chicken repertoire is suggestive that it plays an important
functional role. While humans and rhesus make functional CDR-
H3 sequences containing a pair of cysteines (Zemlin et al., 2003;
Schroeder, 2006), these are found at low frequency in mature
human B-cells, and they are very rare in mice (Raaphorst et al.,
1997; Zemlin et al., 2003). The high incorporation rate of C in
the chicken CDR-H3 is rendered functional by two mechanisms:
(1) frequent use of D-D junctions (Reynaud et al., 1991) to cre-
ate CDR3s with intra-CDR disulphide bridges and (2) insertion
of single C residues in the VH CDRs 1 and 2 for inter-CDR
disulphide bonding. These covalent bonds between CDRs are
structurally analogous to those observed at high frequency in the
immunoglobulins of other species such as camelids (Harmsen
et al., 2000), sharks (Dooley et al., 2003; Stanfield et al., 2004),
cows (Aitken et al., 1997; Sinclair et al., 1997; O’Brien et al.,
1999), pigs (Li and Aitken, 2004), and even the duckbilled platy-
pus (Johansson et al., 2002). It seems likely that the increased
use of disulphide binding in long CDRs, by several species, may
be highly beneficial to stabilize longer loops that have greater
sequence diversity, but could suffer from a lack of structural rigid-
ity that leads to an entropic penalty during binding interactions
(Wong et al., 2011; Hackel et al., 2010). Mutagenesis studies have
shown that these disulphides, in either IgG or single-domain
antibodies, are essential for both V-domain stability and bind-
ing function (Lee et al., 2006; Fennell et al., 2010; Govaert et al.,
2012).
BEYOND STANDARD IGG STRUCTURES—NATURAL ‘DOMAIN
ANTIBODIES’
Despite being the main format for many successful therapeu-
tics, IgG molecules have some practical limitations as they are
large (∼150 kDa), covalently-linked tetrameric structures that
classically contain two antigen-binding sites. The necessity for
two V-regions to combine and stabilize each other makes it
technically challenging to reduce antibodies to anything smaller
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than the dual-domain single chain Fv (scFv) antibody fragment
(∼30 kDa). The desire for smaller, more stable and monomeric
binding modalities in appropriate indications has led to the
investigation of a logical alternative; modular therapeutics built
from naturally-occurring binding proteins that can be used as a
source of “domain antibodies.” As outlined below, comparative
immunogenetics led to the discovery of non-classical immune
proteins such as the camelid VHH and the shark VNAR (variable
domain of the IgNAR), which can both be isolated as soluble,
stable, monomeric V-domains (Figure 6) (Flajnik and Dooley,
2009; Wesolowski et al., 2009; Flajnik et al., 2011). These single
domain proteins are only ∼12–15 kDa in size and have been the
subject of significant academic and industrial research to char-
acterize their origins and utilities (Muyldermans et al., 2009;
Flajnik et al., 2011). Humanization of VHH antibodies is facile,
as the isolated antibodies are typically close to a human VH
germline sequence. Together with high stability and low aggre-
gation, this gives the humanized VHH antibody theoretically low
immunogenicity risk. To date, the less heavily investigated IgNAR
has not been extensively characterized in humanization studies
and may represent a different challenge from VHH. The VNAR
domain is actually more structurally related to a T-cell receptor
α-domain and has much lower a.a. identity to human homolo-
gous domains. As a result, in this section we concentrate on the
more experimentally advanced VHH.
Domain antibodies, lacking an Fc region, suffer from fast
renal clearance and without protein engineering they have short
in vivo half-lives. Luckily, the stable, soluble nature of isolated
domain antibodies renders then relatively simple to engineer in
a modular fashion. Modifications at the N- or C-terminus are
typically possible without loss of function, allowing fusion to
common half-life extension molecules such as serum albumin
FIGURE 6 | Ribbon representation of Llama VHH (left) and Shark
IgNAR (right) in complex with Hen Egg White Lysozyme (HEL). PDBID
1OP6 was used to represent the VHH:HEL complex. PDBID 2I26 was used
to represent the IgNAR:HEL complex. Note the protruding IgNAR CDR-H3
blocking the active site of HEL, which contrasts with the bended VHH
CDR-H3 that recognizes a flat epitope. The Figure was generated using
PyMOL.
or immunoglobulin Fc and covalent conjugation to natural or
non-natural polymers that expand the hydrodynamic radius of
the proteins, greatly reducing renal clearance. Domain antibod-
ies have also been extensively exploited as modular units to create
bispecific molecules for targeting multiple disease mediators with
a single polypeptide (Gill and Damle, 2006; Harmsen and De
Haard, 2007). A final exciting avenue open to domain antibod-
ies is the possibility of oral administration, e.g., via strains of
Lactobacillus expressing a TNF-specific VHH antibody, which was
efficacious in a murine gut inflammation model (Vandenbroucke
et al., 2010). In the following sections we outline the current state
of knowledge surrounding these molecules and the influence that
combined repertoire and structural analyses have had on their
understanding and application.
THE CAMEL ANTIBODY REPERTOIRE AND VHH
In 1993, the Hamers’ group identified a previously unknown
immunoglobulin form observed in camel serum (Hamers-
Casterman et al., 1993). This new immunoglobulin was found
not only to lack a light chain, but to have also deleted the CH1
domain in the heavy chain, following the loss of the splice con-
sensus site (Nguyen et al., 1999). These unique, “heavy chain
antibodies” were shown to have a VHH-Hinge-CH2-CH3 struc-
ture and performed their antigen binding function exclusively via
a stable and soluble VH domain, subsequently dubbed “VHH.”
VHH antibodies were found to be fully functional constituents of
the immune repertoire of camels, representing >50% of the total
Ig population in serum samples (Muyldermans and Lauwereys,
1999; Nguyen et al., 2001). Later studies have shown that other
camelids such as llama and alpaca also share these unusual
immunoglobulins (Harmsen et al., 2000). The VHH and IgG
camel antibodies can be separated by isotype, with IgG1 using
architecture of conventional antibodies, whereas the IgG2 and
IgG3 isotypes are associated with VHH antibodies (Flajnik et al.,
2011).
While they are simple in structure, immunogenetics studies
have shown that rather than being a rudimentary evolutionary
form of immunoglobulin, the VHH antibody in camelids was
actually derived from the genes of a conventional IgH locus by
a relatively recent adaptation (Nguyen et al., 2002). Multiple con-
tributory selection pressures have been postulated that might have
driven this evolutionary event including; amyloidosis associated
with a key light-chain sequence, a virus that targeted a light-chain
as a co-receptor, or a simple biophysical pressure to develop high
frequency antibodies with a “protruding” CDR structure that is
highly appropriate for probing cryptic epitopes (Flajnik et al.,
2011). Indeed, multiple co-crystal structures of both VHH (De
Genst et al., 2006) and IgNAR (Stanfield et al., 2004, 2007) in
complex with enzymes have shown the CDRs to protrude into
the active site cleft of the enzyme, neutralizing its function.
Despite relying on a single variable domain for antigen recog-
nition, it has been shown that the VHH repertoire is as com-
plex in sequence diversity as its VH counterpart in camelid
IgG1 (De Genst et al., 2006). Indeed, although camelid VHH
and VH domains are encoded by distinct sets of V-gene seg-
ments, both forms of antibody share some D segments and an
identical JH region (Nguyen et al., 2001). Similar to chickens,
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sequence analysis of camelid VHH domains has shown very
close homology to the human VH3 family, which is also asso-
ciated with relatively high stability and solubility (Ewert et al.,
2002, 2003). Comparative analyses of VHH and VH germline and
repertoire sequences have shown clearly important differences in
their respective structures (Riechmann and Muyldermans, 1999;
Harmsen et al., 2000), with VHH exhibiting higher frequency of
hypermutation hotspots, leading to greater diversity in CDR-H1
and CDR-H2 sequences and length, plus the frequent observa-
tion of clones with long CDRs 1 and 3. In another convergence
with chickens, VHH antibodies frequently use non-canonical
C residues in their CDRs (Govaert et al., 2012). While the disul-
phide bonding patterns seen in camelids are not as varied as those
observed for chickens (Wu et al., 2011), they do lead to disulphide
bonding within the CDR-H3, between CDR-H3 and CDR-H1, or
between CDR-H3 and FR-2, with the cysteine groups outside the
CDR3 typically being placed in very similar positions to those
observed in chickens (IMGT positions 38, 55) (Harmsen et al.,
2000).
Most critical of all known VHH characteristics, are the
hydrophobic to hydrophilic substitutions of four critical residues
in the FR-2, known as the “VHH tetrad.” These residues in the
FW2 are in critical positions where the VH of a conventional IgG
would pack against the VL (Abhinandan and Martin, 2010), pro-
viding hydrophobic binding affinity between the two domains.
The classic substitutions V37F/Y, G44E, L45R, and W47G lead
to a major increase in hydrophilicity of the VHH, allowing it to
fold and function independently, without the need for a stabiliz-
ing VL partner (Harmsen andDeHaard, 2007). This adaptation is
essential for biotechnological use, as it allows expression of VHH
antibodies at high concentration. While some conventional VH
domains can be expressed, they will typically become insoluble at
concentrations above 1mg/ml (Davies and Riechmann, 1994).
Importantly, while long CDR-H3 loops may be common for
some VHH sub-types (particularly in camels) and can contribute
to solubility by folding over the FR-2, in llama VHH the aver-
age CDR-H3 length has been shown to not exceed that observed
for humans (Harmsen et al., 2000). Indeed, experimental anal-
yses of independent VH domains derived from chicken IgGs,
which do use long CDRs (Wu et al., 2011) but do not contain
the FR-2 “tetrad” substitutions, have shown that these domains
do not exhibit high solubility and do lose binding affinity when
separated from a light chain partner (Finlay et al., unpublished
observations). Long CDR-H3 sequences are therefore not a guar-
antee of FR-2 coverage or solubility in VHH and the FR-2 tetrad
appears to be an essential factor in achieving solubility. Studies
on the “camelization” of VH domains isolated from mono-
clonal IgG antibodies have corroborated this, by showing that the
addition of the FR-2 tetrad mutations can significantly improve
the solubility of those domains (Davies and Riechmann, 1994;
Riechmann and Muyldermans, 1999). Nonetheless, camelized
and/or CDR-solubilized human antibody domains struggle to
replicate the qualities of natural VHH, (Barthelemy et al., 2008)
suggesting that combined FR and CDR repertoire content may
also play a major role. At the time of writing, no major repertoire
analyses have been performed for VHH in the way they have for
humans, mice and chickens (Zemlin et al., 2003; Wu et al., 2011).
MAN-MADE ANTIBODY REPERTOIRES
Phage display technology was developed by George Smith in 1985
(Smith, 1985) to display peptides on the surface of the filamen-
tous bacteriophage M13. In an effort to isolate “fully human”
antibodies and thus bypass humanization, phage display was
adapted at the beginning of 1990s (McCafferty et al., 1990) to dis-
play antibody V-domain repertoires and to isolate antibodies of
interest in vitro. During the 1990s and the last decade, several aca-
demic laboratories and biotechnology companies have designed
and implemented human antibody phage-displayed libraries for
antibody discovery (Hoogenboom, 2005; Bradbury, 2010). Such
libraries have enabled the isolation of high affinity and specific
antibodies against a wide range of molecules and the antibody
library design and implementation process continues to evolve.
Since phage display bypasses immunization, it is especially
useful for obtaining antibodies against targets that are highly con-
served across species and those that may be toxic, where in vivo
methods are ineffective and/or impractical. In addition, since
phage display technology allows access to the repertoire of genes
intended for expression and display on the phage surface, the
number of genes and variants can be designed or chosen to bias
the repertoire toward genes with predefined characteristics, open-
ing up the possibility of testing hypotheses on how the size of a
repertoire, its diversity and composition impact the selection of
specific, stable, soluble, and high affinity antibodies. Overviews
of different man-made repertoires and how their performance
has enhanced our knowledge of the evolution of the antibody
repertoire are provided below.
NATURAL (NAÏVE) REPERTOIRES
Originally, human antibody phage-displayed libraries for in vitro
discovery were implemented either by cloning the natural reper-
toire of rearranged antibody genes (Marks et al., 1991) or by
rearranging human antibody germ-line genes in vitro (Griffiths
et al., 1994). This first generation of natural or naïve repertoires
contained the diversity harvested from the total B-cell repertoire
by RT-PCR and thus suffered from a lack of control over FR
usage and mutation rate (Sidhu and Fellouse, 2006). This can be
a significant issue in antibody therapeutic development, as not
all human FRs are used at high frequency in the B-cell repertoire
(see above) and, importantly, not all will express well in heterol-
ogous systems or be stable in delivery formulations (Ewert et al.,
2003). Additionally, antibodies from naïve libraries may contain
somatic mutations leading to FR or CDR based T-cell epitopes
and/or aggregation-prone sequences that could potentially lead
to immunogenicity (Harding et al., 2010). As a result, several
research groups have developed fully synthetic antibody reper-
toires in which a few well-expressed and well-behaved scaffolds
are used for the repertoire synthesis and diversity is restricted to
the CDRs (Pini et al., 1998; Sidhu et al., 2004).
SYNTHETIC REPERTOIRES
The earliest experimental synthetic antibody repertoire was based
on single VH and VL scaffolds, introduced limited diversity into
the CDR-H3 alone and was used to generate moderate affin-
ity hits against haptens (Barbas et al., 1992, 1993). This library
exploited basic knowledge of antibody structure and diversity by
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placing random amino acid diversity into the exposed regions of
the CDR-H3. Amino acid randomization was made possible by
the use of PCR and oligonucleotides containing degenerate DNA
sequence in the appropriate CDR-encoding codons. The simplest
forms of degenerate codons used are based on random incorpora-
tion in the first two bases, followed by restricted incorporation in
the third position to either G/T (“NNK” codon) or G/C (“NNS”
codon). Both of these schemes predominantly incorporate func-
tional diversity, as they encode for 32 codons total, including
only one of the three stop codons (amber) and encoding all 20
amino acids, although not at equal ratio. These codons there-
fore incorporate a reasonable number of translatable polypeptide
sequences, so long as the number of contiguous codons used is
not so many that one stop codon would be expected per clone.
One complicating factor is the obligate encoding of cysteine by
each of these codons, leading to a significant number of clones
in which thiol groups are presented unpaired, leading to loop
malfunction and reducing the overall functional content of the
library.
This very simple method of diversification of key CDR loops
was exploited by a series of teams (Griffiths et al., 1993, 1994;
Viti et al., 2000; Silacci et al., 2005), who used similar methods
to diversify both the CDRs H3 and L3 in a variety of FRs, while
maintaining key loop stem residues in the CDR-H3 such as Kabat
93, 94, 101, and 102. Despite the simple nature of these reper-
toires, they have been highly successful at generating antibodies
to proteins, peptides, and haptens. The isolated antibodies have
proven utility as immunochemical reagents (Neri et al., 1998)
and some have even been applied successfully in therapeutic set-
tings (Neri et al., 1995; Carnemolla et al., 1996; Borsi et al.,
1998; Brack et al., 2006; Silacci et al., 2006). This antibody con-
struction style was then progressed by examining the additional
benefit of adding synthetic diversity in the CDRs 1 and 2 of VH
and exploiting the use of a variety of tailored (A.K.A. “parsi-
monious”) degenerate codons that encoded a smaller number of
amino acids at key positions. This improved the quality of the
resulting libraries, so they encoded a larger proportion of func-
tionally folded clones and the avoidance of stop codons allowed
the incorporation of greater length diversity in the CDR-H3 (Lee
et al., 2004; Sidhu et al., 2004).
Further examination of the amino acid content of the mature
human, primate and rodent V-gene repertoires, coupled with
expanded structural understanding of antibody-antigen inter-
actions, as outlined above, subsequently created highly defined
knowledge of positional amino acid usage in CDRs. These stud-
ies strongly suggested that the key amino acids used in making
functional contacts with protein antigens were highly biased and
the adoption of TRInucleotide, or “TRIM” technology (Virnekas
et al., 1994) allowed the first opportunities for this knowledge
to be fully exploited. TRIM technology is a method based on
classical oligonucleotide synthesis chemistry, but at positions of
randomization, mixes of trinucleotide phosphoramidites (A.K.A.
trimers) are added instead of a series of single base mixes. Each
trimer is a fully synthetic codon and the use of precise com-
binations of these trimers therefore allows the incorporation of
positional bias in amino acid mutagenesis libraries (Virnekas
et al., 1994).
The earliest use of TRIM technology in antibody repertoire
construction did not exploit its full capability, only introducing
fully random amino acid diversity into the CDR-H3 of a single
framework pair and selecting the library successfully against a
series of haptens (Braunagel and Little, 1997). Subsequent land-
mark studies, however, took the use of trinucleotides to its logical
conclusion and attempted to closely mimic the natural human
immune repertoire in synthetic form (Knappik et al., 2000; Rothe
et al., 2008; Prassler et al., 2011). Knappik et al. (2000) gener-
ated the first iteration of the HuCal© libraries, in which they first
recognized that 95% of all human antibody diversity is repre-
sented in only seven VH and seven VL germline gene families.
This observation inspired them to create a library of V-genes built
on consensus FRs derived via alignment of each of these fami-
lies. Into these FRs they placed double-stranded CDR diversity
“cassettes” that had been built using trinucleotides to represent
each of the amino acids naturally found at all positions in CDRs
H3 and L3. They also included length diversity in the CDR3s
and canonical structural determinants for the L3, approximately
mimicking the natural biases observed in the human repertoire.
In the CDR-H3, the natural dominance of G and Y in the human
repertoire was closely reflected, with those two residues making
up approximately 15% each, of the encoded residues between
Kabat 95 and 100s. All other residues were included at ∼4% other
than cysteine, which was allowed at only ∼1% to allow potential
generation of the disulphide-constrained loops that are occasion-
ally observed in the human repertoire. Stem loop biases in both
the CDRs H3 and L3 were also closely maintained and limited
diversity was introduced at several key positions in the struc-
turally conserved Vκ and Vλ L3 loops. This repertoire design was
highly effective in generating nM-affinity clones with specificity
for a selection of proteins and peptides (Knappik et al., 2000;
Marget et al., 2000).
The methods used by Knappik et al. (2000) have since been
elaborated upon in a number of reports. Rothe et al. (2008),
reported the construction of the next-generation library HuCal
Gold™ in which the design strategy was refined to change the
CDR design complexity, the structural format of the library (to
Fab fragment) and also to move to “CysDisplay” in which the
expressed antibody is tethered to the phage via a disulphide bond
with a mutant p3 protein. In this library, the CDR diversity was
extended to the CDRs 1 and 2 of both V-domains, in addition to
the CDR3s. The CDR cassettes were again based on trinucleotide
technology and were built to accurately reflect the canonical
structures and diversity found in the families upon which each
of the consensus frameworks were built, consciously including
structures known to be preferred in the recognition of peptides.
The finalized library was found to be of very high practical util-
ity, routinely generating antibody specificities and affinities in the
single digit nM range that were useful for both therapeutic and
reagent purposes (Jarutat et al., 2006, 2007; Ohara et al., 2006;
Prassler et al., 2009). This library design had, however, made a
critical concession to optimize its function in E. coli expression
and phage display technology: the FRs were codon optimized
specifically to maximize for E. coli periplasmic expression rate.
In addition, this function had been aggressively selected for by
pre-screening all antibody sequences for periplasmic transport
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as β–lactamase fusions before inclusion in the final library. This
resulted in a high frequency of antibodies being selected that
performed very well in prokaryotic expression, but poorly in
mammalian cell lines used for industrial production of IgGs. As
a result, a third iteration “HuCal Platinum™” has since been
made which further updated the design and performance of these
synthetic libraries, by optimizing codon use to suit both prokary-
otic and eukaryotic expression systems (Prassler et al., 2011).
This library also further refined the FR use and CDR content to
minimize T-cell epitope content and maximize similarity to the
human repertoire, by adding length-dependent positional amino
acid bias in the CDR-H3 and by switching some VH gene families
to fully germline (e.g., VH3-23). These changes made the library
higher performing than the HuCal Gold™library in diversity of
hits generated, average affinity and expression rate in mammalian
cells. Similar libraries that have recently been generated by sep-
arate groups have also strongly supported the broad utility and
quality of libraries that naturally mimic the human immune sys-
tem and that these libraries are flexible in display format as they
can be selected by alternative phage display systems such as pIX
display (Shi et al., 2010).
The overall HuCal™ story is therefore a clear paradigm and
example of the intrinsic attraction of synthetic antibody libraries:
they can be designed to add positive attributes and to minimize
negatives. While fully human natural cDNA-derived libraries are
simple to construct and highly functional, negative attributes
such as unwanted FR use, somatic hypermutation in frameworks
and potential liability sequences such as aggregation motifs,
deamidation sites, N-linked glycosylation motifs, oxidation sensi-
tivities and non-canonical disulphide content cannot be avoided
as a rule. The very latest libraries make use of a novel DNA syn-
thesis technology known as Slonomics, which has been shown to
be an excellent method for the synthesis of molecular diversity, as
it allows the production of precise amino acid/codon biases and
low dysfunctional sequence content at any given position (Zhai
et al., 2011). Analysis of the first large library generated using
this technology strongly supports another benefit of carefully
designed synthetic antibody libraries: the removal of segmen-
tal linkage within the CDR-H3 that limits paratope structural
diversity. While natural CDR-H3 sequences have the benefit of
being selected for function in the B-cell, synthetic versions are not
generated by IGV-D-IGJ recombination mechanisms and there-
fore, escape potential limitations on self-reactivity that may be
imposed by natural tolerance mechanisms (Zhai et al., 2011).
Such synthetic antibody libraries are clearly a mature technology
and have become an important section of the armamentarium
currently in use for therapeutic human antibody discovery.
MINIMALIST REPERTOIRES
A series of illuminating studies set out to examine the validity
of the suggestion that only certain amino acids, with particular
emphasis on Y (see above), are essential in the formation of a
functional antibody repertoire (Fellouse et al., 2004, 2005, 2006,
2007; Birtalan et al., 2008, 2010; Fisher et al., 2010). It was postu-
lated that antibody critical contacts were predominantlymediated
by Y and that small amino acids played a critical support role in
creating conformational flexibility and diversity, especially in the
CDR-H3 (Koide and Sidhu, 2009). To examine this hypothesis,
large phage libraries of human Fabs on a single FR combina-
tion were synthesized containing only four amino acids; Y, A,
D, and S in solvent-exposed CDR positions, including CDR-H3
(Fellouse et al., 2004). These libraries were capable of generating
high affinity and specific antibodies, including antibodies of 2 nM
affinities for VEGF. Remarkably, when the four amino acid code
was reduced to only Y and S, highly functional repertoires could
still be generated, (Fellouse et al., 2005, 2007) with structural
studies subsequently showing that Y was indeed the key residue
for making critical contacts with antigen, while serine predomi-
nantly provided structural flexibility and “space” to accommodate
the bulky Y side-chains (Fellouse et al., 2006).
Importantly, Birtalan et al. (2010) have since progressed these
studies and demonstrated that W is the only natural amino acid
that can be used as a functional alternative to Y in experimen-
tal synthetic antibody libraries based on binary diversity (Birtalan
et al., 2010). Indeed, co-crystal structure analysis of an antibody
from a W/S-containing repertoire with its target HER2 showed
clearly that W is a key determinant of the binding specificity
(Fisher et al., 2010). Additionally, these investigators have shown
that excess content of highly charged residues such as R is a signif-
icant risk factor for the high frequency generation of polyreactive
clones (Birtalan et al., 2008, 2010). A subsequent study performed
using a set of libraries of synthetic single-domain binding pro-
teins has provided supporting evidence for the idea that minimal
diversity can be genuinely functional, but that increased amino
acid diversity overall is still the best for high function (Hackel
and Wittrup, 2010). Synthetic antibody libraries have, there-
fore, not only allowed the interrogation of fundamental antibody
structure/function relationships, but have illustrated what library
design elements are critical to maximal function. Future studies
will most likely continue to advance this field to make synthetic
diversity as reliable as possible.
RATIONAL REPERTOIRES
Finally, based on the finding that the anatomy of the antigen-
binding site determines the propensity to recognize a defined type
of generic antigen such as a peptide or a hapten, it has been
hypothesized that by biasing an antibody repertoire toward the
recognition of predefined antigens the probability of obtaining
more specific and higher affinity antibodies may increase. This
can be rationalized in terms that, when general purpose reper-
toires, such as naïve or synthetic repertoires, are used to obtain
antibodies to a given target, a vast region of the shape space has
to be explored to produce specific antibodies. Provided that only
an infinitesimally small fraction of all possible functional antigen-
binding sites can be explored by using enrichment technologies,
such an exploration should be sparse. Consequently, the prob-
ability of selecting specific antibodies of higher affinity should
increase in repertoires that have been designed to be focused on
predefined regions of the shape space.
Rational repertoires of antibodies are built by selecting genes
encoding combinations of canonical structures that resemble the
structural features of antibodies that bind the desired type of lig-
ands. Sequence diversity is then introduced at residues typically
involved in recognition of those types of targets. For instance, two
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antibody repertoires have been designed and tested for peptide
recognition (Cobaugh et al., 2008). First, a human anti-peptide
repertoire was constructed by pairing the human IGVH germ
line gene 3–23 with a variant of the IGVK germline gene 3–20.
The CDR-L1 of the gene 3–20 was modified to encode a long
loop, typical of anti-peptide antibodies (Figure 7) and diversity
was engineered in VH SDRUs of anti-protein and anti-peptide
antibodies (see above). Another repertoire was generated using
the V-regions of the murine antibody 26–10, which was origi-
nally isolated, based on its affinity to the hapten digoxin, but also
binds peptides and exhibits a canonical structure pattern typical
of anti-peptide antibodies. As in the first repertoire, diversity was
introduced in VH only, using the profile of amino acid found at
positions that frequently contact peptide antigens. Both reper-
toires yielded binders to two model peptides, angiotensin and
neuropeptide Y, following screening by solution phage panning.
The repertoire built onto the 26–10 scaffold yielded antibodies
with affinities below 20 nM to both targets.
Another example of a rational repertoire (Persson et al., 2006)
was designed using as scaffold the antibody FITC8, which has a
cavity in the antigen-binding site, common to anti-hapten anti-
bodies. In five CDRs, diversity was designed on the basis of a 3D
model structure of FITC8 and anti-hapten SDRUs. In addition,
length variation was introduced into the CDR-H2, as longer ver-
sions of this loop have been shown to correlate with increased
hapten binding. The repertoire was cloned, phage-displayed and
screened against a panel of five haptens, yielding diverse and
highly specific binders to four of the selectors. Parallel selections
FIGURE 7 | Model of the human anti-peptide (left) and mouse
anti-peptide (right) repertoires. On the top, side view of the Connolly
surface of the models. Bottom, models seen from the antigen perspective.
Invariant VLs are colored in brown. VHs are colored in gray. Within the
antigen-binding site, green represents fully randomized positions, i.e.,
20 amino acids; blue positions diversified to Tyr, Asp, Ala, and Ser; red
positions diversified to incorporate the most common anti-peptide SDRs.
PDBID: 1MCP and 2IGF were used as template for modeling human
VL and VH, respectively. Coordinates of the antibody 26-10 (PDBID 1IGI)
were used for modeling the mouse anti-peptide repertoire. The models
and Figures were created in Discovery Studio.
were performed with a repertoire having diversity inmore periph-
erally located residues, which are more often found in contact
with protein than haptens. The binders selected from the control
(anti-protein) repertoire were not able to bind to the soluble hap-
ten in the absence of the carrier protein, in contrast to the clones
selected from the anti-hapten repertoire. Thus, although more
validation is needed in order to conclude that rational repertoires
increase the probability of obtaining more specific and higher
affinity antibodies, these two examples have shown the feasibil-
ity and potential advantages of designing repertoires to recognize
predefined generic ligands.
CONCLUSIONS AND FUTURE DIRECTIONS
In this review, we have outlined the importance of the con-
tinuum of knowledge that runs through antibody structural
studies, species repertoire analyses and experimental exploitation
of this information to design antibody repertoires and advance
antibody-based drug discovery. Study of hundreds of x-ray crys-
tallography antibody structures free and bound to wide variety of
ligands have provided a detailed picture of how antibodies rec-
ognize diverse types of ligands with exquisite specificity and high
affinity. It has also shown that, although the antigen-binding site
is very diverse in sequence and structure, it has predictable geo-
metrical features that determine the types of generic ligands with
which the antibody interacts. This knowledge has been critical to
understand the mechanisms of the immune response mediated
by antibodies and the evolution of the antibody repertoire. Its
application has led to the development of engineering methods
such as humanization, antigen-affinity optimization and effector
function enhancement, which have made possible the approval of
more than 30 antibody-based medicines in the last two decades.
The knowledge gained on the antibody structure has been
complemented with the study of the antibody repertoire of several
species. In addition to humans, we described in previous sec-
tions the repertoires and the affinity maturation mechanisms of
mice and chickens, plus the use of novel single-domain antibodies
in camelids and sharks. These species all utilize diverse evolu-
tionary solutions to generate specific and high affinity antibodies
and illustrate the plasticity of natural antibody repertoires. Their
comparative study has raised fundamental questions about the
evolutionary factors shaping the antibody repertoire such as: has
the evolution of the antibody repertoire been a stochastic process
or has it been shaped by functional and/or structural constraints?
What is the optimal size and diversity of a repertoire that can be
generated in vitro in order to generate specific and high affinity
antibodies to a wide variety of antigen types?
Multiple variations of man-made antibody repertoires have
been designed and validated in the last two decades, which have
served as tools to explore the above conundrums on how the
evolution, size, diversity, and composition of a repertoire impact
the selection of more specific and higher affinity antibodies to
any given target. A first generation of man-made antibodies
included all the antibody genes encoding the repertoire of cir-
culating antibodies, but a relatively limited subset of the genes
predominated the panning of the repertoires, showing that many
genes are dispensable. A second generation of synthetic reper-
toires followed. Learning the lesson from the study of natural
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and man-made naïve repertoires, the new generation of synthetic
human antibody repertoires was built on single or a few well-
behaved scaffolds. The diversity in these libraries was designed to
mimic that of the natural antibodies. These repertoires produced
antibodies to a vast array of the diverse antigens. In a further
round of design and testing, minimalist repertoires have been
designed and validated. These repertoires have been designed to
display antigen-binding sites made of very few amino acids or
even only binary Y/S and W/S mixes, again yielding antibod-
ies specific against diverse antigens. Finally, rational repertoires
encoding genes with predefined recognition features have been
tested, which hold the promise of increasing the probability of
obtaining more specific and higher affinity antibodies.
Looking forward into the future, new technologies such as
next generation sequencing (NGS) are providing the means
to study whole natural (Weinstein et al., 2009; Jiang et al.,
2011) and man-made repertoires (Glanville et al., 2009) in
expedited ways and at relatively low costs (Fischer, 2011;
Benichou et al., 2012). Having access to the complete infor-
mation encoded in repertoires before and after selection under
diverse selection pressures, combined with faster and more
accurate 3D modeling methods (Almagro et al., 2011; Kuroda
et al., 2012) and indeed new conceptual tools and algorithms
such as network analysis, may reveal new features of anti-
body repertoires. These findings will hopefully further impact
the theories addressing the origin and evolution of antibody
binding specificity. It will also inform the design and opti-
mization of man-made repertoires to isolate more potent,
stable, safe and efficacious antibody-based therapeutics, at a
lower cost.
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